The U.S. Anti-Doping Agency (USADA) has released a statement today regarding the suspension terms for BJ Penn for his admitted IV violation.
During an out-of-competition test on March 25, 2016, Penn declared the use of an intravenous infusion of a non-prohibited substance. A subsequent investigation by USADA revealed that the intravenous infusion received by Penn was administered in a volume greater than 50 mL within a 6 hour period. Under the UFC Anti-Doping Policy, intravenous infusions in a volume greater than 50 mL within a 6 hour period are prohibited, except for those legitimately received in the course of hospital admissions, surgical procedures or clinical investigations. Intravenous infusions received in any other setting require an approved Therapeutic Use Exemption (TUE).
Penn, 37, voluntarily disclosed his use of the intravenous infusion and fully cooperated with USADA’s investigation into the circumstances regarding his violation. Under the UFC Anti-Doping Policy, the standard period of ineligibility may be reduced due to an individual’s voluntary admission of a violation and/or pursuant to an analysis of the individual’s degree of fault for the violation. Here, after taking both of those factors into consideration, USADA determined that a 6-month period of ineligibility was an appropriate sanction under the rules for Penn’s violation.
USADA conducts the year-round, independent anti-doping program for all UFC athletes. USADA is an independent, non-profit, non-governmental agency whose sole mission is to preserve the integrity of competition, inspire true sport, and protect the rights of clean athletes. The anti-doping program run by USADA for UFC athletes includes education, science and research, testing, and results management. Official UFC Anti-Doping Program information and athlete resources are available at UFC.USADA.org.